Precision Diagnosis and Care for Families With Pulmonary Fibrosis in Ireland

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

July 1, 2026

Study Completion Date

April 1, 2028

Conditions
Connective Tissue DiseasesInterstitial Lung DiseaseIdiopathic Pulmonary FibrosisFamilial Idiopathic Pulmonary FibrosisPulmonary FibrosisPulmonary Fibrosis Interstitial
Interventions
DIAGNOSTIC_TEST

Six minute walk test (6MWT)

Assessment of exercise capacity by the carrying out of a 6MWT at 0, 6 and 12 months.

DIAGNOSTIC_TEST

Computer-tomography of the thorax (CT Thorax)

Radiological assessment via CT Thorax, preferably high-resolution CT thorax at baseline on entering the study and at one year. CT images will be collected on study end. CT images in all subjects will be evaluated by three readers blinded to any other interpretation and conforming to ATS-guidelines. Coded data from CT scans will be shared with our collaborator Professor Simon Walsh at Imperial College, London who will use computational methods to identify novel radiologic phenotypes linked to disease behaviour of our patient's fibrotic lung disease.

OTHER

Quality of life questionnaires.

Qality of life questionnaires including; modified Medical Research Council (mMRC) dyspnea scale, The King's Brief Interstitial Lung Disease Questionnaire (KBILD), The Leister Cough Questionnaire and the EQ-5D-3L questionnaire are measured at 0, 6 and 12 months

DIAGNOSTIC_TEST

Genetic Testing

10ml of serum will be collected for DNA extraction and analysed for causative and at risk genetic mutations

DIAGNOSTIC_TEST

Spirometry

We will carry out spirometry at baseline, 6 and 2 months including forced vital capacity and diffusing capacity of the lungs for carbon monoxide.

DIAGNOSTIC_TEST

Serology

Serology which may indicate an underlying diagnosis of ILD will be carried out on study entry. This will include a full blood count, renal profile, liver profile, C-reactive protein, creatine kinase, erythrocyte sedimentation rate, antinuclear antibodies, anticyclic citrullinated peptide antibodies, rheumatoid factor, an extended myositis antibody panel, sjögren's antibodies, scleroderma antibodies and a hypersensivity pneumonitis panel if clinically indicated.

OTHER

Other Quality of Life Questionnaires

Patient Global Assessment and Clinician Global Assessment scores completed at 0, 6 and 12 months

OTHER

PatientMPower Home Monitoring App

Continuous at home monitoring of patients using home-based digital spirometry and pulse-oximetry with real-time feedback readings to patient and clinician. Smartphone app for patients, spirometer and pulse oximeter are connected to the app via Bluetooth. Patients are asked to take 2 readings per week.

Trial Locations (1)

D09V2N0

RECRUITING

Beaumont Hospital, Dublin

All Listed Sponsors
collaborator

patientMpower Ltd.

INDUSTRY

collaborator

Imperial College London

OTHER

lead

Royal College of Surgeons, Ireland

OTHER